Suppr超能文献

伽玛刀治疗库欣病

Gamma Knife surgery for Cushing's disease.

作者信息

Jagannathan Jay, Sheehan Jason P, Pouratian Nader, Laws Edward R, Steiner Ladislau, Vance Mary Lee

机构信息

Department of Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia 22908-00212, USA.

出版信息

J Neurosurg. 2007 Jun;106(6):980-7. doi: 10.3171/jns.2007.106.6.980.

Abstract

OBJECT

In this study the authors address the efficacy and safety of Gamma Knife surgery (GKS) in patients with adrenocorticotropic hormone-secreting pituitary adenomas.

METHODS

A review of data collected from a prospective GKS database between January 1990 and March 2005 was performed in patients with Cushing's disease. All but one patient underwent resection for a pituitary tumor, without achieving remission. Successful endocrine outcome after GKS was defined as a normal 24-hour urinary free cortisol (UFC) concentration posttreatment after a minimum of 1 year of follow up. Patient records were also evaluated for changes in tumor volume, development of new hormone deficiencies, visual acuity, cranial nerve neuropathies, and radiation-induced imaging changes. Ninety evaluable patients had undergone GKS, with a mean endocrine follow-up duration of 45 months (range 12-132 months). The mean dose, to the tumor margin was 23 Gy (median 25 Gy). Normal 24-hour UFC levels were achieved in 49 patients (54%), with an average time of 13 months after treatment (range 2-67 months). In the 49 patients in whom a tumor was visible on the planning magnetic resonance (MR) image, a decrease in tumor size occurred in 39 (80%), in seven patients there was to change in size, and tumor growth occurred in three patients. Ten patients (20%) experienced a relapse of Cushing's disease after initial remission; the mean time to recurrence was 27 months (range 6-60 months). Seven of these patients underwent repeated GKS, with three patients achieving a second remission. New hormone deficiencies developed in 20 patients (22%), with hypothyroidism being the most common endocrinopathy after GKS. Five patients experienced new visual deficits or third, fourth, or sixth cranial nerve deficits; two of these patients had undergone prior conventional fractionated radiation therapy, and four of them had received previous GKS. Radiation-induced changes were observed on MR images in three patients; one had symptoms attributable to these changes.

CONCLUSIONS

Gamma Knife surgery is an effective treatment for persistent Cushing's disease. Adenomas with cavernous sinus invasion that are not amenable to resection are treatable with the Gamma Knife. A second GKS treatment appears to increase the risk of cranial nerve damage. These results demonstrate the value of combining two neurosurgical treatment modalities-microsurgical resection and GKS-in the management of pituitary adenomas.

摘要

目的

在本研究中,作者探讨了伽玛刀手术(GKS)治疗促肾上腺皮质激素分泌型垂体腺瘤患者的疗效和安全性。

方法

对1990年1月至2005年3月从一个前瞻性GKS数据库收集的数据进行回顾性分析,纳入库欣病患者。除1例患者外,所有患者均接受了垂体肿瘤切除术,但未实现缓解。GKS术后成功的内分泌结局定义为至少随访1年后治疗后24小时尿游离皮质醇(UFC)浓度正常。还评估了患者记录中的肿瘤体积变化、新的激素缺乏症的发生、视力、颅神经病变以及放射诱导的影像学变化。90例可评估患者接受了GKS治疗,内分泌平均随访时间为45个月(范围12 - 132个月)。肿瘤边缘的平均剂量为23 Gy(中位数25 Gy)。49例患者(54%)实现了24小时UFC水平正常,治疗后平均时间为13个月(范围2 - 67个月)。在计划磁共振(MR)图像上可见肿瘤的49例患者中,39例(80%)肿瘤大小减小,7例大小无变化,3例肿瘤生长。10例患者(20%)在初次缓解后出现库欣病复发;复发的平均时间为27个月(范围6 - 60个月)。其中7例患者接受了重复GKS治疗,3例患者实现了第二次缓解。20例患者(22%)出现了新的激素缺乏症,甲状腺功能减退是GKS后最常见的内分泌病。5例患者出现了新的视力缺陷或第三、第四或第六颅神经缺陷;其中2例患者曾接受过传统分次放射治疗,4例接受过GKS治疗。3例患者在MR图像上观察到放射诱导的变化;1例患者出现了与这些变化相关的症状。

结论

伽玛刀手术是治疗持续性库欣病的有效方法。无法切除的侵犯海绵窦的腺瘤可用伽玛刀治疗。第二次GKS治疗似乎会增加颅神经损伤的风险。这些结果证明了在垂体腺瘤的治疗中联合两种神经外科治疗方式——显微手术切除和GKS——的价值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验